Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Living Cell Technologies ( (AU:1AI) ) has shared an update.
Algorae Pharmaceuticals has signed a definitive licence and supply agreement with India’s Cadila Pharmaceuticals to launch two generic medicines for cardiovascular and metabolic disorders in Australia and New Zealand. Under the deal, Cadila will handle development and manufacturing, while Algorae, via its AlgoraeRx unit, will act as TGA sponsor and lead regulatory and commercial efforts across the region.
The Cadila tie-up builds on Algorae’s existing oncology-focused licensing arrangement with Sakar Healthcare for five generic cancer drugs and its recent distribution deal with Dr. Reddy’s for Capecitabine 500 mg in Australia. Together, these partnerships are building a multi-partner, multi-therapy platform that broadens Algorae’s product base across oncology, cardiovascular and metabolic diseases, strengthening its presence with hospitals, pharmacies and institutional buyers in Australia and New Zealand.
The most recent analyst rating on (AU:1AI) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on Living Cell Technologies stock, see the AU:1AI Stock Forecast page.
More about Living Cell Technologies
Algorae Pharmaceuticals is an ASX-listed, AI-enabled pharmaceutical company focused on drug-combination discovery and pharmaceutical commercialisation. Its proprietary AlgoraeOS platform uses artificial intelligence to identify synergistic drug combinations, while its AlgoraeRx division licenses and supplies generic and specialty medicines in Australia and New Zealand through manufacturing partners and established distribution channels.
YTD Price Performance: 64.29%
Average Trading Volume: 2,412,978
Technical Sentiment Signal: Buy
Current Market Cap: A$38.84M
For detailed information about 1AI stock, go to TipRanks’ Stock Analysis page.